A Novel Device for Rapid and Noninvasive Volatile Metabolite-based Screening and Diagnosis of Multiple Disease States
一种基于挥发性代谢物的快速、无创筛查和诊断多种疾病状态的新型装置
基本信息
- 批准号:10426603
- 负责人:
- 金额:$ 102.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-10 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptionAnimalsBiologicalBiological AssayBiosensing TechniquesBlindedCharacteristicsClinicalCommunicable DiseasesDetectionDevelopmentDevicesDiagnosisDiagnosticDiagnostic EquipmentDiagnostic testsDiseaseEnrollmentEnsureEnvironmental Risk FactorEvaluationFunctional disorderGas ChromatographyGasesHumanIndividualInflammatoryInfluenzaMalignant - descriptorMental disordersMetabolicMetabolismMonitorMorbidity - disease rateOlfactory PathwaysOutcomePatientsPopulationProcessReproducibilityResearch DesignSamplingSkinSmell PerceptionSourceSpecificitySpectrometryStandardizationStudy SubjectTechnologyTestingTherapeuticTimeTrainingTranslatingWorkbasecase controlcomorbiditydesigndetection limitdiagnostic strategydiagnostic tooldisease diagnosishuman diseaseimprovedmachine learning methodmeetingsnervous system disordernovelpoint of careportabilityrapid detectionscreeningskin organogenesisvolatile organic compoundwearable sensor technology
项目摘要
Project Summary/Abstract: Humans emit an array of volatile organic compounds (VOCs) as part of
normal metabolism. There are metabolic shifts in many disease states, and animals with highly sensitive
olfactory systems can be trained to identify patients with certain diseases based on their characteristic scent.
We seek to translate detection of these unique VOCs emanating through the skin to a more robust,
standardized, and mechanized platform, readily adaptable for the screening, diagnosis, and monitoring of a
variety of human disease states with distinct pathophysiologies. We hypothesize that systemic metabolic
derangements in many high burden infectious, inflammatory, metabolic, malignant, psychiatric, and
neurologic diseases can be identified via skin emissions. We will adapt a novel, portable gas chromatography-
differential mobility spectrometry (GC-DMS) device that rapidly examines volatile samples directly at the point
of care for the assessment of these skin volatile metabolite signatures. This device is highly sensitive, allowing a
comprehensive and biologically representative assessment of the landscape of human volatile emissions, is
more robust to confounding and environmental factors than many other gas sensing devices, has a long track
record of successful use in various real-world sensing applications, and is already undergoing commercial
development, which will greatly facilitate its rapid development for the skin VOC-based diagnosis of these 20
disease states. We propose further development and rigorous evaluation of this scent-based diagnostic
approach to these disease states, (1) integrating additional process analytical technologies (PATs) to ensure
instrumental accuracy and precision between samples and devices through repeated, high-volume patient
testing over time and modifying the device inlet for skin volatile analysis, (2) identifying and validating GC-
DMS signatures and the corresponding set of skin volatile metabolites that distinguish individuals with and
without each of these 20 disease states using machine learning methods, integrating automated detection of
these signatures on the GC-DMS device, and (3) developing a wearable sensor for at least one disease with a
simple volatile signature, determining the test characteristics of this wearable diagnostic device. A lack of
reproducibility is a major issue plaguing the field of volatile metabolite analysis, often due to confounding and
study design flaws. We will make every effort to minimize and eliminate any sources of confounding, bias, and
extraneous variability as we develop and evaluate this scent-based diagnostic approach, to yield generalizable
signatures for each disease state. Ultimately, successful completion of these aims will yield rapid, noninvasive
skin volatile metabolite assays for the screening, diagnosis, and monitoring of each of these diseases, with a
clear, binary (yes/no) assessment of whether the individual has evidence of one or more of these diseases,
facilitating early administration of appropriate therapeutics in these patients and mitigating the clinical
consequences of each of these diseases.
项目摘要/摘要:人类排放一系列挥发性有机化合物(VOCs)作为
新陈代谢正常。在许多疾病状态下都会有代谢变化,而高度敏感的动物
可以训练嗅觉系统,根据患者特有的气味识别患有某些疾病的患者。
我们试图将对这些通过皮肤散发的独特VOCs的检测转化为更强大的、
标准化和机械化平台,易于适应筛查、诊断和监测
人类疾病的各种状态,具有不同的病理生理学。我们假设全身新陈代谢
许多高负担的传染病、炎症性疾病、代谢疾病、恶性疾病、精神疾病和
神经系统疾病可以通过皮肤排泄物来识别。我们将采用一种新型的便携式气相色谱仪-
差示迁移率光谱分析(GC-DMS)设备,可直接快速检测挥发性样品
用于评估这些皮肤挥发性代谢物的特征。该设备高度敏感,允许
对人类挥发性排放的地貌进行全面和具有生物学代表性的评估,是
与许多其他气体传感设备相比,它对混杂和环境因素的适应能力更强,需要很长的时间
在各种真实世界传感应用中的成功使用记录,并已进入商业化阶段
开发,这将极大地促进其快速开发基于皮肤VOC的诊断这20
疾病状态。我们建议进一步开发和严格评估这种基于气味的诊断方法
针对这些疾病状态的方法,(1)集成其他过程分析技术(PATS)以确保
通过重复、大容量患者的样本和设备之间的仪器准确度和精密度
随着时间的推移测试和修改设备入口以进行皮肤挥发性分析,(2)识别和验证GC-
DMS特征和相应的皮肤挥发性代谢物集合,区分患有和
没有使用机器学习方法的这20种疾病状态中的每一种,集成了
GC-DMS设备上的这些签名,以及(3)开发一种可穿戴的传感器,用于至少一种疾病
简单的挥发性特征,决定了这款可穿戴诊断设备的测试特性。缺乏
重复性是困扰挥发性代谢物分析领域的一个主要问题,通常是由于混淆和
研究设计缺陷。我们将尽一切努力最大限度地减少和消除任何混淆、偏见和
当我们开发和评估这种基于气味的诊断方法时,无关的可变性,以产生可推广的
每个疾病状态的签名。最终,这些目标的成功实现将产生快速、非侵入性的
皮肤挥发性代谢物分析用于筛查、诊断和监测每一种疾病,具有
对个人是否有一种或多种此类疾病的证据进行明确的二元(是/否)评估,
促进这些患者的早期应用适当的治疗方法,减轻临床
这些疾病的每一种的后果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sophia Koo其他文献
Sophia Koo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sophia Koo', 18)}}的其他基金
A Novel Device for Rapid and Noninvasive Volatile Metabolite-based Screening and Diagnosis of Multiple Disease States
一种基于挥发性代谢物的快速、无创筛查和诊断多种疾病状态的新型装置
- 批准号:
10663172 - 财政年份:2022
- 资助金额:
$ 102.41万 - 项目类别:
Breath Volatile Metabolites for the Diagnosis of Coccidioidomycosis
呼吸挥发性代谢物用于球孢子菌病的诊断
- 批准号:
10312113 - 财政年份:2020
- 资助金额:
$ 102.41万 - 项目类别:
Rapid, Breath Volatile Metabolite-Based Diagnostic for In Vivo Identification and Antibiotic Resistance Profiling of Bacterial Pathogens in Ventilator-Associated Pneumonia
基于呼吸挥发性代谢物的快速诊断,用于呼吸机相关肺炎细菌病原体的体内鉴定和抗生素耐药性分析
- 批准号:
10630048 - 财政年份:2018
- 资助金额:
$ 102.41万 - 项目类别:
Rapid, Breath Volatile Metabolite-Based Diagnostic for In Vivo Identification and Antibiotic Resistance Profiling of Bacterial Pathogens in Ventilator-Associated Pneumonia
基于呼吸挥发性代谢物的快速诊断,用于呼吸机相关肺炎细菌病原体的体内鉴定和抗生素耐药性分析
- 批准号:
9922858 - 财政年份:2018
- 资助金额:
$ 102.41万 - 项目类别:
Aspergillus fumigatus Volatile Secondary Metabolite Dynamics for the Identification of Azole-resistant Aspergillosis
烟曲霉挥发性次生代谢动态用于鉴定唑类抗性曲霉病
- 批准号:
9299327 - 财政年份:2017
- 资助金额:
$ 102.41万 - 项目类别:
Volatile Metabolite-Based Detection of Clostridium difficile Infection
基于挥发性代谢物的艰难梭菌感染检测
- 批准号:
9088345 - 财政年份:2015
- 资助金额:
$ 102.41万 - 项目类别:
Breath Volatile Metabolites for the Diagnosis of Emerging Invasive Mold Infection
呼吸挥发性代谢物用于诊断新发侵袭性霉菌感染
- 批准号:
8875578 - 财政年份:2012
- 资助金额:
$ 102.41万 - 项目类别:
Breath Volatile Metabolites for the Diagnosis of Emerging Invasive Mold Infection
呼吸挥发性代谢物用于诊断新发侵袭性霉菌感染
- 批准号:
8443160 - 财政年份:2012
- 资助金额:
$ 102.41万 - 项目类别:
Breath Volatile Metabolites for the Diagnosis of Emerging Invasive Mold Infection
呼吸挥发性代谢物用于诊断新发侵袭性霉菌感染
- 批准号:
8528464 - 财政年份:2012
- 资助金额:
$ 102.41万 - 项目类别:
Breath Volatile Metabolites for the Diagnosis of Emerging Invasive Mold Infection
呼吸挥发性代谢物用于诊断新发侵袭性霉菌感染
- 批准号:
8699494 - 财政年份:2012
- 资助金额:
$ 102.41万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 102.41万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 102.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 102.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 102.41万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 102.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 102.41万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 102.41万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 102.41万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 102.41万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 102.41万 - 项目类别:
Standard Grant